ArticleActa biomaterialia2026
Minimally invasive delivery of engineered heart tissues restores cardiac function in rats with chronic myocardial infarction.
Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background Myocardial infarction leads to irreversible cardiomyocyte loss and adverse ventricular remodeling, often culminating in heart failure. Transplantation of functional cardiac patches offers a promising avenue for myocardial repair, yet current delivery methods typically require open-chest surgery and suturing of the graft, limiting their applicability in patients with severe heart failure. Methods We developed an engineered heart tissue composed of human induced pluripotent stem cell-derived cardiomyocytes, endothelial cells, and fibroblasts seeded on a durable, flexible scaffold. The scaffold was made of intertwined poly lactide-co-glycolide nano- and microfiber hybrid aerogels coated with gelatin of shape-recoverable property, ensuring mechanical resilience and flexibility for thoracoscopic delivery. Engineered heart tissues were loaded with pro-angiogenic factors including fibroblast growth factor 1 and CHIR99021. After in vitro characterization and optimization, engineered heart tissues were delivered to rats via thoracoscopy at 28 days after myocardial infarction induction. Echocardiography and histological analysis were used to assess cardiac function and heart remodeling. Results Engineered heart tissues exhibited structural integrity under mechanical compression. Thoracoscopy-based epicardial engineered heart tissue transplantation to rats with chronic myocardial infarction significantly improved left ventricular ejection fraction and fractional shortening, concomitant with reduced fibrosis, cardiomyocyte apoptosis, and inflammation, as well as enhanced vascularization. Furthermore, engineered heart tissues modulated the immune response by decreasing neutrophil and macrophage infiltration. Conclusions These findings establish the feasibility of a minimally invasive approach for delivery of engineered heart tissues, eliminating the need for suturing and offering a less invasive alternative to transplantation, thereby broadening the clinical potential of engineered heart tissue-based therapy for heart failure. STATEMENT OF SIGNIFICANCE: Transplantation of engineered heart tissues emerges as a promising approach for regenerating myocardium and improving cardiac function in preclinical models of heart failure. However, clinical translation remains challenged due to the invasive nature of current delivery methods, which often involve open-chest procedures that pose significant risks, particularly for patients with severe heart failure. This study introduces an engineered heart tissue (EHT) made from human induced pluripotent stem cells-derived cardiac cells on a flexible scaffold, and shows that EHTs can be delivered to animal models of chronic myocardial infarction using a minimally invasive, video-assisted thoracoscopic approach. This approach offers a safer alternative to open-chest surgery for EHT treatment of patients with end-stage heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.